Patent intelligence · US
US 7678387
Drug delivery systems
Drug delivery systems
Patent details — US 7678387
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 16, 2010
- Expiration
- Mar 11, 2030
- Applicant
- Capricorn Pharma Inc.
- Claims
- 18
- CPC classes
- A61K, A61K9/2018, A61K9/2072
Quick answer
US 7678387 (Drug delivery systems) is held by Capricorn Pharma Inc.. Status: granted. Granted Mar 16, 2010. Expires Mar 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Capricorn Pharma Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K9/2018, A61K9/2072
More from Capricorn Pharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9616107
Therapy for kidney disease and/or heart failure
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 7678387?
US 7678387 (Drug delivery systems) is held by Capricorn Pharma Inc.. Status: granted. Granted Mar 16, 2010. Expires Mar 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7678387?
Capricorn Pharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 7678387 expire?
Our index shows an expiration date of Mar 11, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.